Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function

被引:9
|
作者
Dib, Sergio A. [1 ]
Gomes, Marilia B. [2 ]
机构
[1] Univ Fed Sao Paulo, Dept Med, Div Endocrinol, Sao Paulo, SP, Brazil
[2] Univ Estado Rio De Janeiro, Dept Med, Diabet Div, Rio De Janeiro, GB, Brazil
来源
关键词
PROTEIN-TYROSINE-PHOSPHATASE; INSULIN AUTOANTIBODIES; C-PEPTIDE; GLYCEMIC CONTROL; ONSET; AUTOIMMUNITY; RELATIVES; GENE; EXPRESSION; DISEASE;
D O I
10.1186/1758-5996-1-25
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 1A diabetes mellitus (T1ADM) is a progressive autoimmune disease mediated by T lymphocytes with destruction of beta cells. Up to now, we do not have precise methods to assess the beta cell mass, "in vivo" or "ex-vivo". The studies about its genetic susceptibility show strong association with class II antigens of the HLA system (particularly DQ). Others genetics associations are weaker and depend on the population studied. A combination of precipitating events may occur at the beginning of the disease. There is a silent loss of immune-mediated beta cells mass which velocity has an inverse relation with the age, but it is influenced by genetic and metabolic factors. We can predict the development of the disease primarily through the determination of four biochemically islet auto antibodies against antigens like insulin, GAD65, IA2 and Znt8. Beta cell destruction is chronically progressive but at clinical diagnosis of the disease a reserve of these cells still functioning. The goal of secondary disease prevention is halt the autoimmune attack on beta cells by redirecting or dampening the immune system. It is remains one of the foremost therapeutic goals in the T1ADM. Glycemic intensive control and immunotherapeutic agents may preserve beta-cell function in newly diagnosed patients with T1ADM. It may be assessed through C-peptide values, which are important for glycemic stability and for the prevention of chronic complications of this disease. This article will summarize the etiopathogenesis mechanisms of this disease and the factors can influence on residual C-peptide and the strategies to it preservation.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] β-Cell mass versus function in type 1 diabetes mellitus: truth or dare?
    Teresa Rodriguez-Calvo
    Mark Atkinson
    Matthias von Herrath
    Nature Reviews Endocrinology, 2017, 13 : 1 - 1
  • [22] RESIDUAL B-CELL FUNCTION AND INSULIN SENSITIVITY IN TYPE-1 (INSULIN-DEPENDENT) DIABETES-MELLITUS
    BONORA, E
    COSCELLI, C
    BUTTURINI, U
    DIABETOLOGIA, 1983, 25 (03) : 298 - 298
  • [23] Impact of flash glucose monitoring on glycemic control varies with the age and residual β-cell function of patients with type 1 diabetes mellitus
    Zhang, Liyin
    Xu, Yaling
    Jiang, Xiaofang
    Wu, Jieru
    Liu, Fang
    Fan, Li
    Li, Xia
    Yin, Guangming
    Yang, Lin
    JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (03) : 552 - 559
  • [24] BETA-CELL RESIDUAL FUNCTION IN JUVENILE DIABETES-MELLITUS
    SCHOBER, E
    SCHERNTHANER, G
    FRISCH, H
    MONATSSCHRIFT KINDERHEILKUNDE, 1980, 128 (12) : 776 - 779
  • [25] Prognostic Factors for the Development of Amputations in People with Type 2 Diabetes Mellitus
    Horacio Orozco-Covarrubias, Victor
    Enrique Cabrera-Pivaral, Carlos
    de los Angeles Aguilera-Velasco, Maria
    Alfaro-Alfaro, Noe
    Gonzalez-Galvez, Guillermo
    Leticia Sanchez-Michel, Blanca
    JOURNAL OF RESEARCH IN MEDICAL AND DENTAL SCIENCE, 2019, 7 (02): : 219 - 224
  • [26] Prognostic factors for the course of β cell function in autoimmune diabetes
    Törn, C
    Landin-Olsson, M
    Lernmark, Å
    Palmer, JP
    Arnqvist, HJ
    Blohmé, G
    Lithner, F
    Littorin, B
    Nyström, L
    Scherstén, B
    Sundkvist, G
    Wibell, L
    Östman, J
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (12): : 4619 - 4623
  • [27] Hypoglycemia in children with type 1 diabetes mellitus - Risk factors, cognitive function, and management
    Ryan, CM
    Becker, DJ
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1999, 28 (04) : 883 - +
  • [28] Cell therapies for type 1 diabetes mellitus
    Shamblott, MJ
    Clark, GO
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (03) : 269 - 277
  • [29] Cell replacement in type 1 diabetes mellitus
    Hayek, A
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2005, 18 : 1157 - 1161
  • [30] Prognostic value of endothelial dysfunction in type 1 diabetes mellitus
    Ladeia, Ana Marice
    Sampaio, Raphael Ribeiro
    Hita, Maiara Costa
    Adan, Luis F.
    WORLD JOURNAL OF DIABETES, 2014, 5 (05): : 601 - 605